NanoVibronix Inc (NAOV)
Official siteMEDICAL DEVICES
Last updated: Dec 10, 2025 at 4:00 PM ET
NanoVibronix Inc (NAOV) Financials: Revenue, Profit and Cash Flow
NanoVibronix reported revenue of $2.56M for the fiscal year ended Dec 31, 2024, up 12.0% from the year before. That year, net income was -$3.71M with a net margin of -144.8%, operating cash flow was -$2.52M and free cash flow was -$2.52M. The quarter ended Sep 30, 2025 had revenue of $722.00K and net income of $510.00K.
Revenue and Margins
Over the 9 years to Dec 2024, revenue grew from $147.00K, a compound annual rate of 37.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $2.56M | +12.0% | 59.0% | -140.0% | -144.8% |
| Dec 2023 | $2.28M | +203.6% | 67.3% | -150.5% | -162.5% |
| Dec 2022 | $752.00K | -55.6% | 22.2% | -666.5% | -724.5% |
| Dec 2021 | $1.70M | +172.1% | 45.4% | -335.3% | -842.6% |
| Dec 2020 | $623.00K | +17.5% | 34.3% | -757.5% | -694.4% |
| Dec 2019 | $530.00K | +66.7% | 53.0% | -971.9% | -1093.2% |
| Dec 2018 | $318.00K | +33.1% | 50.3% | -1353.1% | -1306.3% |
| Dec 2017 | $239.00K | +4.4% | 63.2% | -1293.3% | -2077.4% |
| Dec 2016 | $229.00K | +55.8% | 61.6% | -1011.4% | -1236.2% |
| Dec 2015 | $147.00K | N/A | 66.7% | -968.7% | -1961.9% |
Income Statement
In the fiscal year ended Dec 2024, the net loss was unchanged from the year before. In the quarter ended Sep 2025, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.56M | $2.28M | $752.00K | $1.70M | $623.00K | $530.00K | $318.00K | $239.00K | $229.00K | $147.00K |
| Cost of revenue | $1.05M | $746.00K | $585.00K | $925.00K | $409.00K | $249.00K | $158.00K | $88.00K | $88.00K | $49.00K |
| Gross profit | $1.51M | $1.54M | $167.00K | $770.00K | $214.00K | $281.00K | $160.00K | $151.00K | $141.00K | $98.00K |
| Research and development | $909.00K | $185.00K | $283.00K | $293.00K | $171.00K | $514.00K | $614.00K | $693.00K | $584.00K | $399.00K |
| Operating income | -$3.58M | -$3.44M | -$5.01M | -$5.68M | -$4.72M | -$5.15M | -$4.30M | -$3.09M | -$2.32M | -$1.42M |
| Net income | -$3.71M | -$3.71M | -$5.45M | -$14.28M | -$4.33M | -$5.79M | -$4.15M | -$4.96M | -$2.83M | -$2.88M |
| EBITDA | N/A | -$3.44M | N/A | N/A | -$4.16M | N/A | -$4.28M | N/A | N/A | N/A |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $722.00K | $494.00K | $1.02M | $444.00K | $376.00K | $817.00K | $921.00K | $1.18M | $458.00K | $294.00K | $354.00K | -$102.00K |
| Gross profit | N/A | -$35.00K | $369.00K | $283.00K | $133.00K | $428.00K | $664.00K | $737.00K | $349.00K | $216.00K | $235.00K | -$300.00K |
| Operating income | N/A | -$3.98M | -$1.85M | -$1.37M | -$970.00K | -$674.00K | -$568.00K | -$702.00K | -$670.00K | -$1.01M | -$1.05M | -$1.71M |
| Net income | $510.00K | -$156.00K | -$2.50M | -$1.43M | -$998.00K | -$688.00K | -$588.00K | -$813.00K | -$727.00K | -$1.07M | -$1.10M | -$2.06M |
Balance Sheet
As of Dec 2024, cash and equivalents of $752.00K were 20.7% of total assets of $3.63M, against total liabilities of $3.00M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.63M | $6.67M | $5.88M | $8.62M | $8.23M | $2.04M | $1.58M | $4.87M | $494.00K | $1.98M |
| Current assets | $3.33M | $6.49M | $5.61M | $8.34M | $7.97M | $1.84M | $1.23M | $4.52M | $221.00K | $1.78M |
| Cash and equivalents | $752.00K | $3.28M | $2.71M | $7.74M | $7.14M | $1.34M | $896.00K | $4.36M | $106.00K | $1.61M |
| Total liabilities | $3.00M | $2.69M | $2.65M | $2.31M | $5.83M | $688.00K | $1.12M | $1.23M | $2.99M | $2.19M |
| Shareholder equity | $627.00K | $3.99M | $3.23M | $6.31M | $2.39M | $1.35M | $463.00K | $3.63M | -$2.50M | -$209.00K |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $54.38M | $51.48M | $44.10M | $3.63M | $4.68M | $5.70M | $6.24M | $6.67M | $7.36M | $3.83M | $4.81M | $5.88M |
| Total liabilities | $11.92M | $11.01M | $8.43M | $3.00M | $2.81M | $2.85M | $2.73M | $2.69M | $2.67M | $2.67M | $2.61M | $2.65M |
| Cash and equivalents | $6.95M | $4.03M | $601.00K | $752.00K | $1.30M | $2.17M | $2.70M | $3.28M | $3.79M | $253.00K | $1.51M | $2.71M |
| Shareholder equity | $42.46M | $40.48M | $35.67M | $627.00K | $1.87M | $2.84M | $3.50M | $3.99M | $4.69M | $1.17M | $2.20M | $3.23M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.52M | -$3.60M | -$7.04M | -$4.37M | -$3.39M | -$3.87M | -$3.55M | -$2.18M | -$1.53M | -$1.48M |
| Capital expenditures | $3.00K | $1.00K | $3.00K | $3.00K | $2.00K | $2.00K | $8.00K | $8.00K | $8.00K | $1.00K |
| Free cash flow | -$2.52M | -$3.60M | -$7.04M | -$4.37M | -$3.39M | -$3.88M | -$3.56M | -$2.19M | -$1.54M | -$1.48M |
| Investing cash flow | -$3.00K | -$1.00K | -$3.00K | -$3.00K | -$2.00K | -$2.00K | -$8.00K | -$8.00K | -$8.00K | -$1.00K |
| Financing cash flow | $1.00K | $4.22M | $2.09M | $4.58M | $9.52M | $4.32M | $94.00K | $6.44M | $33.00K | $3.00M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.97M | -$3.38M | -$1.34M | -$548.00K | -$836.00K | -$553.00K | -$579.00K | -$491.00K | -$682.00K | -$1.23M | -$1.20M | -$1.33M |
| Capital expenditures | $28.00K | $4.00K | $5.00K | $0 | $0 | $2.00K | $1.00K | $0 | $0 | $0 | $1.00K | $1.00K |
| Free cash flow | -$2.00M | -$3.39M | -$1.35M | -$548.00K | -$836.00K | -$555.00K | -$580.00K | -$491.00K | -$682.00K | -$1.23M | -$1.20M | -$1.33M |
Frequently Asked Questions About NAOV
What is NanoVibronix's annual revenue?
NanoVibronix reported revenue of $2.56M for the fiscal year ended Dec 31, 2024.
How fast is NanoVibronix's revenue growing?
Revenue was up 12.0% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was 14.7%.
Is NanoVibronix profitable?
No. NanoVibronix reported net income of -$3.71M for the fiscal year ended Dec 31, 2024, with a net margin of -144.8%.
How much free cash flow does NAOV generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of -$2.52M minus capital expenditures of $3.00K produced free cash flow of -$2.52M.
How much debt does NanoVibronix have?
The balance sheet dated Dec 31, 2024 reported cash and equivalents of $752.00K.
NAOV pages: Overview, Financials